ArticleStress and health : journal of the International Society for the Investigation of Stress2025
Transdiagnostic Effects of a Chinese Herbal Formula DEP-2306 on Improving Sleep and Mood in Adults With Depressive Episode With Insufficient Symptoms: A Real-World Study.
Article in Stress and health : journal of the International Society for the Investigation of Stress, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transdiagnostic Effects of a Chinese Herbal Formula DEP-2306 on Improving Sleep and Mood in Adults With Depressive Episode With Insufficient Symptoms: A Real-World Study.Stress and health : journal of the International Society for the Investigation of Stress · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to characterize the changes in sleep and mood and assess the safety of a Chinese herbal formula Depression (DEP)-2306 in adults with a depressive episode with insufficient symptoms (DEIS). Additionally, it explored the factors associated with the outcome remission with significant improvement. Between June 2023 and January 2024, 67 DEIS patients were administered daily DEP-2306 over 4 weeks. The main outcomes included depression severity (Patient Health Questionnaire-9 [PHQ-9] and Hamilton depression rating scale [HAMD-17]), anxiety severity (General Anxiety Disorder-7 [GAD-7]), and sleep quality (Pittsburgh Sleep Quality Index [PSQI]). A linear mixed model was used to analyse the score changes, and logistic regression was used to identify factors associated with the outcome remission with significant improvement, which was defined as a PHQ-9 score ≤ 4 and a ≥ 50% reduction from baseline. The results demonstrated that there were significant reductions in PHQ-9 scores from 11.8 to 6.7 (p < 0.01, Cohen's D = 1.55), GAD-7 scores from 10.6 to 6.0 (p < 0.01, Cohen's D = 1.03), and PSQI scores from 10.3 to 7.9 (p < 0.01, Cohen's D = 0.76). 38.6% (22 out of 57) of the participants achieved remission with significant improvement. Further analyses indicated that the presence of attitudinal barriers towards conventional psychological/psychiatric treatments and lower sleep disturbance scores at baseline increased the likelihood of achieving remission with significant improvement. The 4-week DEP-2306 intervention significantly alleviated symptoms of depression and anxiety, and improved sleep quality, suggesting a potential transdiagnostic outcome in DEIS. It was particularly responsive in individuals with attitudinal barriers and milder sleep disturbances at baseline. Trial Registration: This real-world study was retrospectively registered with the International Traditional Medicine Clinical Trial Registry (ITMCTR2025000835) on April 24, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.